Anavex Life Sciences Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Terrie Kellmeyer
- Full Time Employees
- 34
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 630 5th Avenue New York NY United States 10111
- IPO Date
- Apr 13, 2006
- CIK
- 0001314052
- Website
- anavex.com
- Similar Companies
- Business
- Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on the development of innovative small molecule therapeutics for the treatment of central nervous system (CNS) diseases, including Alzheimer's disease, Parkinson’s disease dementia, schizophrenia, and rare neurodevelopmental disorders such as Rett syndrome. The company's core product is ANAVEX®2-73 (blarcamesine), an orally available Sigma-1 receptor (SIGMAR1) and muscarinic receptor agonist designed to restore cellular homeostasis by targeting protein misfolding, mitochondrial dysfunction, and autophagy processes. Anavex’s precision medicine platform leverages proprietary SIGMACEPTOR™ technology to develop scalable treatments that potentially modify disease progression across a range of neurodegenerative and neurodevelopmental disorders. The company’s clinical pipeline includes completion of multiple Phase 2 and Phase 3 trials for ANAVEX®2-73 in Alzheimer's disease, Parkinson’s disease dementia, and Rett syndrome, with ongoing plans for further pivotal studies including schizophrenia-related disorders. Recently, Anavex has entered a strategic partnership with Partex NV, leveraging Partex’s proprietary artificial intelligence technology to enhance its precision medicine drug development platform and patient experience ecosystem, extending beyond R&D into healthcare sales and marketing. In 2025, Anavex reported positive clinical trial results demonstrating continued long-term benefit of oral blarcamesine in early Alzheimer's disease patients with notable cognitive and biomarker improvements compared to natural history controls. The company is actively pursuing regulatory re-examination following a negative initial opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding the marketing authorization application for blarcamesine. Other ongoing development milestones include advancing ANAVEX®3-71 for schizophrenia-related disorders and designing Phase 2/3 trials for Fragile X syndrome. Anavex maintains a commitment to precision medicine approaches and patient-centric innovation across its geographic operations primarily focused in the United States and Europe. Founded in 2005 and headquartered in New York, Anavex Life Sciences operates as a publicly traded company listed on NASDAQ under the ticker AVXL. The company targets underserved patient populations with high unmet medical needs in neurodegenerative and neurodevelopmental CNS disorders, aiming to bring novel treatment paradigms through its orally administered small molecule therapies. This description reflects the company's current product focus, strategic alliances, regulatory activities, clinical pipeline developments, and operational status as of late 2025.
Company News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL
ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
ROSEN, LEADING INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
DEADLINE ALERT for Fluence Energy, Inc. (FLNC), Qfin Holdings, Inc. (QFIN), Endava plc (DAVA), and Anavex Life Sciences Corp. (AVXL): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions
Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm
AVXL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026
Kaplan Fox Alerts Anavex Life Sciences Corp. (AVXL) Investors Who Suffered Losses to a Securities Class Action - Deadline is November 30, 2026
ROSEN, LEADING INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL
Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026
Deadline Alert: Anavex Life Sciences Corp. Investors Have Until November 30, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
Kaplan Fox Reminds Anavex Life Sciences Corp. (AVXL) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 30, 2026
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
ROSEN, RECOGNIZED TRIAL ATTORNEYS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL
AVXL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026
ROSEN, A LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL
Did You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXL